Pharmaceutical

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Dec 20, 2023 - 18:00
GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood o...

Next Article

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC grants approval to Pfizer for $43bn Seagen acquisition 

EC grants approval to Pfizer for $43bn Seagen acquisition 

Oct 21, 2023

TLM-101 by Therillume for Neurofibromatoses Type I (Von...

Nov 6, 2023

Opinion: Without a plan to fight superbugs, the Cancer Moonshot will never achieve liftoff

Opinion: Without a plan to fight superbugs, the Cancer ...

Aug 3, 2023